Search results for "reparation"

showing 10 items of 944 documents

Review and update on drugs related to the development of osteonecrosis of the jaw

2019

Conflict of interest Conclusions of the working group on “New drugs related to the de-velopment of osteonecrosis of the jaw”. Spanish Society of Cranio-mandibular Dysfunction and Orofacial Pain and Spanish Society of Oral Medicine SEDCYDO-SEMO joint International Meeting: 30th SEDCYDO annual meeting & 15th SEMO Congress. Bilbao (Spain); June, 2019. [EN] Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or a…

medicine.medical_specialtyBevacizumabReviewMRONJ03 medical and health sciencesantiresorptives0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectGeneral DentistrybisphosphonatesAfliberceptBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industrySunitinibOsteonecrosis030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]osteonecrosis of the jawantiangiogenicsDenosumabOtorhinolaryngologyPharmaceutical PreparationsUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Neurocognition in bipolar disorders—A closer look at comorbidities and medications

2010

The last decade has witnessed a growing interest in the neuropsychological study of bipolar disorder (BD). This chronic mood disorder is associated with persistent neurocognitive impairments even during periods of euthymia, particularly in the broad domains of attention, verbal memory and executive functions. More interestingly, cognitive dysfunction seems to predict a poorer functional outcome among BD patients and thus represents an important target for future therapies. The aetiology of cognitive dysfunction is probably multifactorial, including gene-environment interactions with potentially confounding variables as well. Drug-induced cognitive adverse effects represent an important and …

medicine.medical_specialtyBipolar disorderComorbidityLithiumAntipsychoticNeuropsychologyAnticonvulsantmedicineAnimalsHumansBipolar disorderPsychiatryPharmacologyNeuropsychologyCognitionIatrogenic effectmedicine.diseaseExecutive functionsComorbidityPharmaceutical PreparationsObservational studyVerbal memoryCognition DisordersPsychologyNeurocognitiveClinical psychologyEuropean Journal of Pharmacology
researchProduct

Oxycodone extended release capsules for the treatment of chronic pain

2017

As a consequence of greater prescription opioid utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious risks. Associated new formulations may be safer. Areas covered: The introduction of abuse-deterrent opioid formulations and continuous programs to improve opioid prescribing practices may limit the opioid abuse and its consequences. Oxycodone extended release capsules are an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e.g., chewing, crushing). Studies have reported that this preparation is efficacious in patients with low back pain, le…

medicine.medical_specialtyCapsules03 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineHumansPharmacology (medical)In patientChildIntensive care medicinebusiness.industryGeneral NeuroscienceChronic painHave Difficulty Swallowingmedicine.diseaseLow back painAnalgesics OpioidOpioidPrescription opioidDelayed-Action PreparationsAnesthesiaNeurology (clinical)Chronic Painmedicine.symptomExtended releasebusinessOxycodoneOxycodone030217 neurology & neurosurgerymedicine.drugExpert Review of Neurotherapeutics
researchProduct

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct

Oral local drug delivery and new perspectives in oral drug formulation

2012

Modern pharmaceutical science has provided us with a wide range of substances to be administered with a wide large variety of dosage forms. Local drug delivery systems have been used for a long time; in particular, for the local therapy of diseases affecting the oral cavity. Although these diseases are often extremely responsive to local therapy, the mouth often presents various difficulties in the application of topical compounds (owing to saliva and the mouth's different functions), resulting in a short retention time of dosage forms with a consequent low therapeutic efficacy. To resolve these limitations, research today concentrates on the development of bioadhesive formulations. This re…

medicine.medical_specialtyChemistry PharmaceuticalBioadhesiveAdministration SublingualPharmaceutical Preparations DentalPharmacologyPermeabilityDosage formPathology and Forensic MedicineDrug Delivery SystemsSettore MED/28 - Malattie OdontostomatologicheAdhesivesAdministration MucosalHumansMedicineRadiology Nuclear Medicine and imagingDentistry (miscellaneous)Pharmaceutical sciencesOral mucosaIntensive care medicineDosage Formsbusiness.industryMouth MucosaAdministration BuccalBuccal administrationDrug delivery Buccal mucosa Buccal dosage formsmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverySurgeryOral SurgerybusinessRetention timeOral retinoid
researchProduct

Compounded preparations in dermatology – analysis of prescribing habits in everyday clinical practice in Germany

2020

Background Compounded preparations (CPs) are an indispensable addition to approved, commercially available drugs (CADs), especially for topical therapy. In Germany, about eight million CPs are prescribed within the statutory health insurance system each year, 50 % thereof by dermatologists. Methods We analyzed prescribing habits based on a questionnaire sent out to 186 office-based dermatologists and 1,491 pharmacies in the federal states of Rhineland-Palatinate and Saarland. The goal was to improve patient care by collecting and categorizing data in terms of prescription practice and associated challenges in interdisciplinary cooperation. Results Overall, 351 pharmacists (23.5 %) and 53 de…

medicine.medical_specialtyDrug CompoundingMEDLINEContext (language use)PharmacyDermatologyPharmacistsSkin Diseases030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineContinuing medical educationGermanySurveys and QuestionnairesHumansMedicinePractice Patterns Physicians'Medical prescriptionPharmaciesbusiness.industryCompounded preparationsTopical medicationClinical PracticeCross-Sectional StudiesFamily medicineDermatologic AgentsbusinessDermatologistsJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Real‐world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon‐…

2020

Abstract Aim To assess the impact of the timing of initiating both basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on reaching glycaemic control targets over 6 and 12 months in people with type 2 diabetes (T2D) uncontrolled on oral antihyperglycaemic drugs with an HbA1c of 9% or higher. Methods This retrospective cohort study assessed the impact of the timing of initiating both basal insulin and GLP‐1 RA therapies on reaching glycaemic targets (HbA1c < 7% and <8%, and ≥1% and ≥2% HbA1c reduction) over 12 months in people with markedly uncontrolled T2D (HbA1c ≥ 9%) on oral antihyperglycaemic drugs identified on the Optum Humedica database (electronic medical records; …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismInsulins030209 endocrinology & metabolismGlycemic ControlType 2 diabetes030204 cardiovascular system & hematologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyGLP‐1 analogueInternal medicinecohort studyInternal MedicineHumansHypoglycemic AgentsInsulinMedicinebasal insulinRetrospective StudiesGlycated Hemoglobindatabase researchbusiness.industryMedical recordHazard ratioRetrospective cohort studyOriginal Articlesmedicine.diseaseGlucagon-like peptide-1Confidence intervalglycaemic controlDiabetes Mellitus Type 2Pharmaceutical PreparationsCohortOriginal Articletype 2 diabetesbusinessCohort studyDiabetes, Obesity and Metabolism
researchProduct

The impact of chocolate on cardiovascular health

2011

Cardiovascular disease is the leading determinant of mortality and morbidity in women. Functional foods are attracting interest as potential regulators of the susceptibility to disease. Supported by epidemiological evidence, chocolate has emerged as a possible modulator of cardiovascular risk. Chocolate, or cocoa as the natural source, contains flavanols, a subclass of flavonoids. The latter years have witnessed an increasing number of experimental and clinical studies that suggest a protective effect of chocolate against atherogenesis. Oxidative stress, inflammation, and endothelial function define three biological mechanisms that have shown sensitivity to chocolate. Moreover, the consumpt…

medicine.medical_specialtyFlavonolsmedicine.medical_treatmentCardiovascular healthPhysiologyDiseaseDark chocolateGeneral Biochemistry Genetics and Molecular BiologyfoodFunctional foodFunctional FoodmedicineAnimalsHumansInsulinWhite chocolateInflammationCacaomedicine.diagnostic_testbusiness.industryInsulinObstetrics and GynecologyCardiovascular AgentsPlatelet ActivationLipidsfood.foodSurgeryCardiovascular DiseasesNatural sourceEndothelium VascularPlant PreparationsbusinessLipid profilePhytotherapyMaturitas
researchProduct

Panintestinal capsule endoscopy in patients with celiac disease

2021

INTRODUCTION Capsule endoscopy has proven its utility in diagnosing villous atrophy and lymphoma in patients with celiac disease. Recently, a novel capsule endoscopy system was introduced which enables the examination of the small and large bowel. So far, it has not been evaluated in patients with celiac disease. OBJECTIVE The primary objective of this study was to evaluate the novel panintestinal capsule endoscopy system in patients with celiac disease. METHODS Eleven patients with histologically proven celiac disease (Marsh 0-IV), who underwent a panintestinal capsule endoscopy between March 2018 and April 2019 at our institution, were included in this retrospective single-center study. A…

medicine.medical_specialtyHepatologyDuodenumbusiness.industryConcordanceGastroenterologyDiseasemedicine.diseaseCapsule Endoscopydigestive system diseasesColon polypslaw.inventionCeliac DiseaseCapsule endoscopylawmedicineBowel preparationHumansDuodenal mucosaIn patientRadiologyIntestinal MucosaVillous atrophybusinessRetrospective StudiesEuropean Journal of Gastroenterology &amp; Hepatology
researchProduct

Split-dose versus whole-dose cleansing preparations for colonoscopy

2006

medicine.medical_specialtyHepatologymedicine.diagnostic_testbusiness.industrySplit doseCleansing preparationsGastroenterologyMedicineColonoscopyGeneral MedicinebusinessSurgeryNature Clinical Practice Gastroenterology &amp; Hepatology
researchProduct